The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 27, No. 12, pp. 1532-1537.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ben-Joseph, R
Right arrow Articles by Russell, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ben-Joseph, R
Right arrow Articles by Russell, W.


Research Articles

Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists

R Ben-Joseph, R Segal, and WL Russell

OBJECTIVE: To identify risk factors for adverse drug reactions (ADRs) in patients receiving intravenous histamine2-receptor antagonists (H2-RAs). DESIGN: The study hypothesis was evaluated by performing a logistic regression procedure with a backward elimination of the explanatory variables associated with ADRs. MAIN OUTCOME MEASURES: ADRs temporally associated with the use of intravenous H2-RAs served as the dependent variable. Background information about the patients and drug use evaluation criteria in three general areas were entered into the regression analysis. SETTING: Hospitals were selected from the southeastern US, based on their willingness to participate and their characteristics. Participating hospitals exhibited a variety of sizes and ownership arrangements. PATIENTS: 1200 adult patients who were receiving intravenous H2-RAs. RESULTS: Seven percent of patients experienced a presumed ADR (PADR) to intravenous H2-RAs. The only risk factor for ranitidine was for patients who did not have their dosage corrected for renal function ("overdose"); these patients were twice as likely to experience a PADR compared with patients who received the correct dosage as determined by their renal function. Two risk factors for cimetidine were identified: (1) patients taking cimetidine with another medication known to cause a drug interaction; and (2) patient age. No risk factors were identified for famotidine. CONCLUSIONS: The two risk factors for ADRs identified in this study are preventable. Healthcare providers should strive to prevent ADRs by adjusting patients' dosages based on their renal function and by monitoring patients receiving cimetidine with another medication known to interact with cimetidine.


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. Manlucu, M. Tonelli, J. G. Ray, A. Papaioannou, G. Youssef, H. R. Thiessen-Philbrook, A. Holbrook, and A. X. Garg
Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence
Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2376 - 2384.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
P. E. Marik
Analytic Reviews : Stress Ulcer Prophylaxis: A Practical Approach
J Intensive Care Med, January 1, 1999; 14(1): 1 - 8.
[PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.